3 years 18
Extreme 18
62
5 years 13.6
Extreme 13.6
77.7
10 years 13.6
Extreme 13.6
96.48
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/01/2023
Compliance Officer - 01/01/2022
Investor Relations Contact - 01/08/2018
Date Insider Type Main position Quantity % Market Cap. Importance
7/1/25 A Issuer sale

Director

85,011 0.1134%
7/1/25 A Issuer sale

Chief Financial Officer

738,955 0.9861%
7/1/25 A Issuer sale

Chief Technology Officer

151,946 0.2028%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%-.--% - - 3.54B
-0.46%+10.31%+63.52%+143.15% 1,257B
-0.97%+1.60%+43.25%+80.09% 651B
-2.05%+0.73%+32.47%+101.62% 510B
+0.11%-0.40%+53.14%+67.50% 388B
-0.78%+5.51%+72.55%+44.25% 366B
+0.90%+3.04%+33.37%+59.23% 303B
+0.69%+8.73%+12.76%+35.75% 288B
-0.12%+4.68%+55.97%+74.59% 252B
-0.21%+7.34%+42.19%+109.69% 211B
Average -0.22%+4.59%+45.47%+79.54% 469.63B
Weighted average by Cap. -0.30%+5.30%+49.34%+93.81%
Logo SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Employees
368
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - SpringWorks Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SWTX Stock